source
- Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumbleTenax Therapeutics announced that its experimental oral levosimendan failed to meet the primary efficacy endpoint in the Phase 3 LEVEL study, which evaluated treatment for a form of heart failure l…
- BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme assetBioMarin announced it will stop development of BMN 401, an enzyme replacement therapy acquired in its $270 million purchase of Inozyme Pharma. The decision follows the Phase 3 ENERGY trial in pati…